{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T14:35:14Z","timestamp":1791470114625,"version":"4.3.4"},"reference-count":25,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T00:00:00Z","timestamp":1608595200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This double\u2010blind, randomized, placebo\u2010controlled, dose\u2010ascending, first\u2010in\u2010human study (NCT02766621) assessed the safety, tolerability, and pharmacokinetics (PK) of PF\u201006823859, an anti\u2013interferon \u03b2 monoclonal antibody. Healthy subjects were randomized to single ascending doses (SADs) of intravenous PF\u201006823859 30, 100, 300, 900, or 2000 mg or placebo; to multiple ascending doses (MADs) of subcutaneous PF\u201006823859 100 or 300 mg or placebo (once every 2 weeks for a total of 3 doses); or to MAD of intravenous PF\u201006823859 600 mg or placebo (once every 3 weeks or once every 4 weeks for a total of 2 doses). The incidence, severity, and causal relationship of adverse events (AEs) were assessed, along with immunogenicity and PK. In total, 62 subjects were randomized to treatment (SAD, n\u00a0=\u00a035; MAD, n\u00a0=\u00a027). There were 76 treatment\u2010emergent all\u2010causality AEs in the SAD (PF\u201006823859: n\u00a0=\u00a025; placebo: n\u00a0=\u00a04) and MAD (PF\u201006823859: n\u00a0=\u00a040; placebo: n\u00a0=\u00a07) cohorts. In the SAD cohorts, all treatment\u2010emergent all\u2010causality AEs were mild in severity; 4 AEs of moderate severity were identified in the MAD cohorts. No dose\u2010limiting AEs, serious AEs, treatment\u2010related discontinuations, dose reductions, or deaths occurred. PF\u201006823859 exposure increased dose\u2010proportionally, with half\u2010life values ranging between 23 and 35 days. The estimated subcutaneous bioavailability was 43% to 44%. Immunogenicity incidence rates were low (antidrug antibodies, 12.5%; neutralizing antibodies, 2.1%). No immunogenically related clinical responses of concern were observed. In conclusion, PF\u201006823859 demonstrated an acceptable safety, tolerability, and PK profile that supports clinical development for treating disorders associated with increased interferon \u03b2 levels, such as dermatomyositis or systemic lupus erythematosus.<\/jats:p>","DOI":"10.1002\/cpdd.887","type":"journal-article","created":{"date-parts":[[2020,12,23]],"date-time":"2020-12-23T09:42:16Z","timestamp":1608716536000},"page":"307-316","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Safety, Tolerability, and Pharmacokinetics of PF\u201006823859, an Anti\u2013Interferon \u03b2 Monoclonal Antibody: A Randomized, Phase I, Single\u2010 and Multiple\u2010Ascending\u2010Dose Study"],"prefix":"10.1002","volume":"10","author":[{"given":"Srividya","family":"Neelakantan","sequence":"first","affiliation":[{"name":"Worldwide Research and Development Pfizer Inc  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Oemar","sequence":"additional","affiliation":[{"name":"Worldwide Research and Development Pfizer Inc  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Johnson","sequence":"additional","affiliation":[{"name":"Center for Therapeutic Innovation Pfizer Inc  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Rath","sequence":"additional","affiliation":[{"name":"Pfizer Inc  Collegeville Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Salganik","sequence":"additional","affiliation":[{"name":"Worldwide Research and Development Pfizer Inc  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabe","family":"Berman","sequence":"additional","affiliation":[{"name":"Pfizer Inc  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Pelletier","sequence":"additional","affiliation":[{"name":"Pfizer Inc  Groton Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Cox","sequence":"additional","affiliation":[{"name":"Pfizer Inc  Collegeville Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Page","sequence":"additional","affiliation":[{"name":"Worldwide Research and Development Pfizer Inc  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Messing","sequence":"additional","affiliation":[{"name":"Worldwide Research and Development Pfizer Inc  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanela","family":"Tarabar","sequence":"additional","affiliation":[{"name":"Pfizer Clinical Research Unit  New Haven Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,12,22]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15607"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1312625"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2016.186"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu148"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2015.1082908"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20101664"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri3581"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1191\/096120300674499064"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20464"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0067003"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22928"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912196"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(19)30076-1"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0029161"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208562"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206090"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.139949"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15006"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1800791"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40142"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms160714951"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.icb.7100099"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri1684"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.34632"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.37824"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.887","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpdd.887","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.887","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T19:32:36Z","timestamp":1693683156000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,22]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10.1002\/cpdd.887"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.887","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"value":"2160-763X","type":"print"},{"value":"2160-7648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,22]]},"assertion":[{"value":"2020-03-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}